A Phase 1 Study Exploring the Safety, Tolerability, and Pharmacokinetics of INCB086550 in Japanese Participants With Advanced Solid Tumors
Latest Information Update: 16 Nov 2022
At a glance
- Drugs INCB 086550 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Biosciences Japan
- 27 Jul 2022 Status changed from recruiting to discontinued.
- 08 Jan 2021 Planned initiation date (estimated date for recruitment of the first subject) changed from 15 Dec 2020 to 20 Jan 2021.
- 08 Jan 2021 Status changed from not yet recruiting to recruiting.